0001213900-24-072251.txt : 20240823 0001213900-24-072251.hdr.sgml : 20240823 20240823163536 ACCESSION NUMBER: 0001213900-24-072251 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240822 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240823 DATE AS OF CHANGE: 20240823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 241236781 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 ea021219701-8k_arcabio.htm CURRENT REPORT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2024

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

000-22873

36-3855489

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

10170 Church Ranch Way

Suite 100

Westminster, Colorado

80021

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 940-2100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common		ABIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As previously disclosed, on April 3, 2024, ARCA biopharma, Inc., a Delaware corporation (“ARCA”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (“First Merger Sub”), will merge with and into Oruka Therapeutics, Inc. (“Oruka”), with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the “First Merger”), and Oruka will merge with and into Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), with Second Merger Sub being the surviving entity of the merger (the “Second Merger” and, together with the First Merger, the “Merger”).

Item 5.07 Submission of Matters to a Vote of Security Holders.

In connection with the Merger, ARCA held a special meeting of its stockholders on August 22, 2024 (the “Special Meeting”), at which ARCA’s stockholders voted on the proposals set forth below relating to the Merger Agreement. The proposals are described in detail in ARCA’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 22, 2024 and declared effective by the SEC on July 24, 2024 (the “Definitive Proxy Statement/Prospectus”). The final voting results regarding each proposal are set forth below. There were 14,507,143 shares of ARCA common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding and entitled to vote on July 22, 2024, the record date for the Special Meeting, 9,795,459 shares of ARCA common stock were represented in person or by proxy at the Special Meeting, which number constituted a quorum.

Proposal No. 1. Approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the Proxy Statement/Prospectus, and (ii) the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	9,375,442				41,765				3,690				374,562

Proposal No. 2. Approve an amendment to the amended and restated certificate of incorporation of ARCA (the “ARCA Charter”) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 shares to 545,000,000 (the “Authorized Share Increase Amendment”), in the form attached as Annex G to the Proxy Statement/Prospectus.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	9,353,818				64,105				2,974				374,562

Proposal No. 3. Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA’s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the Proxy Statement/Prospectus (the “Reverse Stock Split Amendment”), if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA’s board of directors and Oruka’s board of directors prior to the First Effective Time or, if Proposal 1 is not approved by ARCA stockholders, determined solely by ARCA’s board of directors.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	9,729,049				64,009				2,401				0

1

Proposal No. 4. Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the Proxy Statement/Prospectus.

This proposal was approved by the requisite vote of the Company’s stockholders.

For				Against				Abstain				Broker Non-Votes
	8,382,645				1,027,657				10,595				374,562

Proposal No. 5. Elect the Class III director, Jacob Ma-Weaver, to ARCA’s board of directors and to hold office until ARCA’s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of this Proposal No. 5 will only have an effect until the completion of the Merger because the composition of ARCA’s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Withheld				Broker Non-Votes
	8,123,965				1,296,932				374,562

Proposal No. 6. Ratify the appointment of KPMG LLP as ARCA’s independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	9,781,878				11,450				2,131				0

Proposal No. 7. Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the “Oruka 2024 Incentive Plan”), which will become effective as of and contingent on the completion of the Merger.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	7,060,386				2,338,980				21,531				374,562

Proposal No. 8. Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “Oruka ESPP” and together with the Oruka 2024 Incentive Plan, the “Plans”), which will become effective as of and contingent on the completion of the Merger.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	7,092,970				2,307,499				20,428				374,562

2

Proposal No. 9. Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger.

This proposal was approved by the requisite vote of ARCA’s stockholders.

For				Against				Abstain				Broker Non-Votes
	9,321,260				91,368				8,269				374,562

Proposal No. 10. Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, Proposal No. 2 and/or Proposal No. 3.

As there were sufficient votes to approve Proposal No. 1, Proposal No. 2 and Proposal No. 3 at the time of the Special Meeting, Proposal No. 10 was not presented to stockholders.

Item 8.01 Other Events.

Following receipt of stockholder approval of all stockholder proposals at the Special Meeting, and as previously disclosed, the Merger is expected to be consummated on August 29, 2024, subject to the satisfaction of the remaining closing conditions under the Merger Agreement.

Following approval of the Reverse Stock Split Amendment at the Special Meeting, on August 22, 2024, the ARCA Board of Directors approved the reverse stock split at a ratio of 1-for-12 shares of Common Stock (the “Reverse Stock Split”). ARCA expects to file the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, whereby every 12 shares of ARCA’s issued and outstanding Common Stock will be converted automatically into one issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and without any change in the par value per share. In addition, at the Special Meeting, ARCA’s stockholders approved an increase in the number of shares of ARCA’s authorized common stock from 100,000,000 shares to 545,000,000 shares in connection with the anticipated closing of the Merger.

Following the consummation of the Merger and the Reverse Stock Split Amendment, ARCA will operate under the name, Oruka Therapeutics, Inc., and its shares are expected to begin trading on The Nasdaq Global Market on a post-Reverse Stock Split and post-Merger basis under the ticker symbol “ORKA” effective with the open of business on Tuesday, September 3, 2024. A new CUSIP number (687604108) and ISIN Number (US6876041087) will be assigned to the Common Stock as a result of the Reverse Stock Split.

When the Reverse Stock Split is effective, every twelve (12) shares of Common Stock issued and outstanding or held as treasury stock will be automatically combined and reclassified into one share of Common Stock. In addition, as a result of the Reverse Stock Split, proportionate adjustments will made to the exercise prices and number of shares of ARCA’s common stock underlying ARCA’s outstanding equity and warrant awards, and to the number of shares of common stock issuable or will be issuable upon conversion of ARCA’s convertible preferred stock, including ARCA’s Series B non-voting convertible preferred stock, par value $0.001 per share, to be issued in connection with the Merger.

On August 23, 2024, ARCA issued a press release announcing approval of the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

3

Forward-Looking Statements

This Current Report on Form 8-K and the exhibits filed or furnished herewith contain forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements include express or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company’s listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing of the proposed Merger (including completion of Oruka’s private placement) and cash runway of the combined company; the expected contribution and payment of dividends in connection with the Merger, including the timing thereof; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates; and other statements that are not historical fact. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger will be those that have been anticipated.

The forward-looking statements contained in this communication are based on current expectations and beliefs concerning future developments and their potential effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger, risks associated with the potential failure to complete the financing transaction in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the transactions contemplated by the Merger, risks associated with ARCA’s continued listing on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined company’s business relationships, operating results and business generally; risks associated with the combined company’s ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks related to the combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; the combined company’s ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; the combined company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; the combined company’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and the combined company’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those risks and uncertainties and other factors more fully described in filings with the Securities and Exchange Commission (“SEC”), including reports filed on Form 10-K, 10-Q and 8-K, in other filings that ARCA makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement/Prospectus described below under “Important Additional Information About the Proposed Transaction Filed with the SEC,” and in other filings made by ARCA with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed transaction, are based on ARCA’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by ARCA, all of which are subject to change. Such forward-looking statements are made as of the date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required by securities and other applicable law.

4

No Offer or Solicitation

This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transactions (the “Proposed Transactions”) between ARCA and Oruka or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description

99.1		Press Release, issued on August 23, 2024.
104		Cover Page Interactive Data File (formatted as Inline XBRL)

5

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ARCA biopharma, Inc. (Registrant)

Date: August 23, 2024	By:	/s/ C. Jeffrey Dekker
		Name:	C. Jeffrey Dekker
		Title:	Chief Financial Officer

6

EX-99.1 2 ea021219701ex99-1_arcabio.htm PRESS RELEASE, ISSUED ON AUGUST 23, 2024

Exhibit 99.1

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Westminster, CO, August 23, 2024 – ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the “Merger”), with a new CUSIP number 687604108 and ISIN number US6876041087.

The reverse stock split was approved by ARCA’s stockholders at ARCA’s special meeting of stockholders held on August 22, 2024 (the “Special Meeting”), to be effected in the Board’s discretion of not less than 1-for-6 and not more than 1-for-12. The final reverse stock split ratio of 1-for-12 was approved by the Board on August 22, 2024.

The reverse stock split is expected to reduce the number of ARCA’s outstanding common stock from approximately 14,507,143 shares to approximately 1,208,928 shares. The number of shares of ARCA’s authorized common stock will not be affected by the reverse stock split, but at the Special Meeting, ARCA’s stockholders approved an increase in the number of shares of ARCA’s authorized common stock from 100,000,000 shares to 545,000,000 shares in connection with the anticipated closing of the Merger. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of ARCA common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which such stockholder would otherwise be entitled multiplied by the closing price per share as reported by The Nasdaq Stock Market LLC on September 3, 2024.

As a result of the reverse stock split, proportionate adjustments will made to the exercise prices and number of shares of ARCA’s common stock underlying ARCA’s outstanding equity and warrant awards, and will become effective as of and contingent on the completion of the Merger, and to the number of shares of common stock issuable or will be issuable upon conversion of ARCA’s convertible preferred stock, including ARCA’s Series B non-voting convertible preferred stock to be issued in connection with the Merger. There will be no change to the par value per share.

Following the closing of the Merger, the combined company’s total issued and outstanding common stock is expected to be approximately 29,490,443 shares, and there are expected to be 5,430,360 shares of common stock underlying pre-funded warrants and 11,428,166 shares of common stock underlying ARCA’s Series B non-voting convertible preferred stock, representing a total of 46,348,969 common-stock equivalents (not including outstanding employee and director equity awards).

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. For more information, please visit www.arcabio.com or follow the company on LinkedIn.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com.

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements include express or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company’s listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing of the proposed Merger (including completion of Oruka’s private placement) and cash runway of the combined company; the expected contribution and payment of dividends in connection with the Merger, including the timing thereof; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates; and other statements that are not historical fact. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger will be those that have been anticipated.

The forward-looking statements contained in this communication are based on current expectations and beliefs concerning future developments and their potential effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger risks associated with the potential failure to complete the financing transaction in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the transactions contemplated by the Merger, risks associated with ARCA’s continued listing on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined company’s business relationships, operating results and business generally; risks associated with the combined company’s ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks related to the combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; the combined company’s ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; the combined company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; the combined company’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and the combined company’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those risks and uncertainties and other factors more fully described in filings with the Securities and Exchange Commission (“SEC”), including reports filed on Form 10-K, 10-Q and 8-K, in other filings that ARCA makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement/Prospectus described below under “Important Additional Information About the Proposed Transaction Filed with the SEC,” and in other filings made by ARCA with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed transaction, are based on ARCA’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by ARCA, all of which are subject to change. Such forward-looking statements are made as of the date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required by securities and other applicable law.

No Offer or Solicitation

This communication is not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transactions (the “Proposed Transactions”) between ARCA and Oruka or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

ARCA biopharma Investor & Media Contact:

Jeff Dekker

720.940.2122

ir@arcabio.com

Oruka Therapeutics Investor Relations Contact:

Alan Lada

650.606.7911

Alan.lada@orukatx.com

EX-101.SCH 3 abio-20240822.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 abio-20240822_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 abio-20240822_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 22, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 22, 2024
Entity File Number	000-22873
Entity Registrant Name	ARCA biopharma, Inc
Entity Central Index Key	0000907654
Entity Tax Identification Number	36-3855489
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10170 Church Ranch Way
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Westminster
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80021
City Area Code	(720)
Local Phone Number	940-2100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common
Trading Symbol	ABIO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://arcabio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports abio-20240822.xsd abio-20240822_lab.xml abio-20240822_pre.xml ea021219701-8k_arcabio.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea021219701-8k_arcabio.htm": { "nsprefix": "ABIO", "nsuri": "http://arcabio.com/20240822", "dts": { "schema": { "local": [ "abio-20240822.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "abio-20240822_lab.xml" ] }, "presentationLink": { "local": [ "abio-20240822_pre.xml" ] }, "inline": { "local": [ "ea021219701-8k_arcabio.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://arcabio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea021219701-8k_arcabio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea021219701-8k_arcabio.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://arcabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-24-072251-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-072251-xbrl.zip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end XML 16 ea021219701-8k_arcabio_htm.xml IDEA: XBRL DOCUMENT 0000907654 2024-08-22 2024-08-22 iso4217:USD shares iso4217:USD shares false 0000907654 8-K 2024-08-22 ARCA biopharma, Inc DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 (720) 940-2100 false false false false Common ABIO NASDAQ false